Hepatocellular carcinoma drug resistance models
Abstract Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. Although drug therapy has been well developed and applied, its clinical efficacy is limited due to primary or acquired drug resistance in most HCC patients. Therefore, it is of great clinical signi...
Saved in:
| Main Authors: | Xiaolu Xie, Yaomin Wang, Ziyi Wang, Lei Zhang, Jun Li, Yaling Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-025-03821-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcoma
by: Maria Cristina Manara, et al.
Published: (2025-07-01) -
In vitro and in vivo drug screens of tumor cells identify novel therapies for high‐risk child cancer
by: Loretta M S Lau, et al.
Published: (2021-12-01) -
Establishing a comprehensive panel of patient-derived xenograft models for high-grade endometrial carcinoma: molecular subtypes, genetic alterations, and therapeutic target profiling
by: Sho Sato, et al.
Published: (2025-06-01) -
GSTA1/CTNNB1 axis facilitates sorafenib resistance via suppressing ferroptosis in hepatocellular carcinoma
by: Shiwen Ma, et al.
Published: (2024-12-01) -
Exploring the mechanism of Naringenin in the treatment of hepatocellular carcinoma based on mRNA sequencing and experimental validation
by: Zheng Zhang, et al.
Published: (2025-07-01)